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A B S T R A C T
The role of macrophages acting as immunologic antitumor effectors and promoters of tumor growth are poorly under-
stood as yet. We investigated the role of macrophage in model of concomitant immunity (CI), a phenomenon of secondary
tumor rejection during the primary tumor growth. It has been shown that the period of CI weakening can coincide with
appearance of tumor metastases. We used mammary carcinoma (MC) artificial lung metastases to evaluate the influence
of macrophages from various period of CI on the development of metastases in mice. Our results indicated that macro-
phages are responsible for the late period of CI weakening and suppression. To investigate weather prostaglandins can
mediate suppressive effect of macrophages we used experiments with indomethacin and we found that inhibition of pros-
taglandin E2 synthesis by indomethacin restored antimetastatic effect of concomitant immune macrophages.
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Introduction
The role of macrophages in tumour disease and its in-
teractions with other cell types, cytokines and diverse
growth factors are poorly understood as yet. The most
obscure is controversial role of macrophages acting as
immunologic antitumor effectors and promoters of tu-
mor growth. Thus, in some tumors and at the some steps
of progression, macrophages may promote neoplastic
proliferation, either directly by producing growth factors
or indirectly, for instance, via the induction of immuno-
suppression or tumor angiogenesis1,2. On the other hand,
the antitumor effect of macrophages is unspecific and
rather powerful in elimination of tumour cells with poor
expression of the MHC molecules or tumour antigens3.
The numerous studies showed direct casual relation-
ship between tumour presence and dysfunction of vari-
ous immunological antitumor mechanisms4,5. It has been
demonstrated that macrophages contribute up to or
more than half of tumor’s mass6. Also, the more aggres-
sive tumors, e.g. colon carcinoma Duke’s C, exhibit pro-
found macrophage infiltration than the same type of tu-
mor in earlier stadium7. It has been shown, that tumor
cells recruit monocytes by production of chemotactic
molecules, such as macrophage chemotactic proteins
MCP-1, MCP-2, MCP-3, M-CSF, GM-CSF and IL-12p40
fragment8,9. Only after activation, the accumulated ma-
crophages in the tumor tissue would exhibit antitumor
cytotoxicity. There are two cytokines, IFN-g and TNF-a,
which have the strongest effect on macrophages activa-
tion. Some other cytokines, e.g. GM-CSF, present in tu-
mour tissue, could act as chemotactic molecule as well as
activators of macrophages10.
Moreover, it has been proved in the various experi-
mental and clinical studies that adoptive transfer of
macrophages could elicit the antitumor immune res-
ponse11. However, experimental trials using macro-
phages have produced different results ranging from ef-
fective antitumor response to inefficacy or even better
tumour growth. These observations could be explained
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by different level of activation of macrophages or rather
various stages of differentiation, because macrophages
could release and express various mediators which act
antitumorocidal or tumor promoting12.
Macrophages stimulate tumor growth by secretion of
immunosuppressive mediators or factors that stimulate
angiogenesis – e.g. prostaglandin E2 (PG E2) that is
thought to have an important regulatory role in immune
responses13. PG E2 could be involved in regulation of the
early stages of lymphocyte or macrophage activation14.
Our previous results indicated that macrophages could
be important in late period of weakening of concomitant
immunity (CI) to tumor15. Concomitant immunity is a
phenomenon of secondary tumor rejection during the
primary tumor growth which was described in many tu-
mor models. It can be induced by both immunogenic and
non-immunogenic factors, but its mechanism and dy-
namic differ, depending on tumor type and experimental
model16. It appears after different time periods (depend-
ing on tumor type and experimental model), attains its
peak and then subsides16. The period of CI weakening
can coincide with appearance of tumor metastases17.
Therefore, the investigation of mechanisms involved in
CI weakening could contribute to better understanding
of metastasing process. To resolve weather prostaglandin
E2 is involved in macrophage role in period of weakening
of concomitant immunity we used indomethacin that is
cyclooxygenase II inhibitor and therefore inhibits the
synthesis of PG E2.
Materials and Methods
Animals
The experiments were carried out in CBA of both
sexes, aged 3 to 4 months and weighting 18 to 24 g. Ani-
mals were maintained in acclimatized cages on a 12h
light- dark cycle and had free access to standard labora-
tory chow and water. All experiments were conducted at
Department of Physiology, School of Medicine, Zagreb
University, Croatia and were approved by the local ethi-
cal committee.
Tumor
Mammary carcinoma (MC) is maintained in our De-
pertment by regular subcutaneous passages. CBA mice
that were previously subcutaneously transplated with
mammary carcinoma, were anesthetized with ketami-
ne/xylazine to perform excision of tumor. Solid MC, after
elimination of necrotic and fibrous tissues, was finely
minced and placed in enzyme solution containing 1000
ml RPMI-1640 medium, 10 ml Hepes sodium salt solu-
tion, 0.1 g DNase, 2500 U of hyaluronidase and 1 g of col-
lagenase (Sigma Aldrich). Twelve ml of solution were
added to 2 g of tumor tissue, centrifugated (2000 g/10
min) at room temperature and washed three times in
PBS. Tumor cells viablility, determined by tripan blue,
was above 95%.
Spleen cell suspension
Mice with different exposure time to subcutaneous
mammary carcinoma were spleen donors. The isoleted
spleens were cut in small pieces using scissors, passed
through a stainless-steel mesh, centrifugated (2400 g/5
min) and washed in PBS three times. Tumor cells viabli-
lity, determined by tripan blue under optical microscope,
was above 95%.
Isolation of macrophages from spleen cell
suspension
Spleen cell suspension (10´106) were resuspended in
RPMI-160 medium supplemented with 10% of fetal bo-
vine serum and incubated at 37°C in a humidified incu-
bator with 5% CO2 for 120 minutes in a plastic petri dish.
After the incubation, petri dishes were washed out twice
with PBS. Adherent spleen cells were collected from the
dish bottom by policeman and resuspended in RPMI-
-1640. The presence of macrophages in supernatant,
tested by Indian ink phagocitosis assay, was above 95%.
The number of viable cells was determined by tripan
blue exclusion under optical microscope and always ex-
ceeded 90%.
Adoptive transfer injection
For adoptive transfer injection we used spleenocytes
suspension or macrophages alone from spleen of a subcu-
taneous mammary carcinoma host from different stages
of concomitant immunity. The number of intravenous in-
jected spleenocytes was equivalent to the number of cells
in one spleen (spleen equivalent=80´106 spleenocytes in
0.5 mL of suspension). The number of adoptive trans-
fered macrophages was 8´106 cells, while the number of
spleenocytes depleted with macrophages was 80´106
cells. Animals were intravenous injected with 1´106 MC
cells one day after adoptive spleenocytes transfer.
Indometacine therapy
Indometacine (kindly gift from Belupo) powder was
dissolved in 95% ethanol until the concentration of 5
mg/ml and then diluted in PBS until the concentration of
200 mol/l. Mice were intraperitonealy injected with 0.2
ml of indometacine solution 3 times in 2 weeks before the
adoptive transfers of cells.
Pulmonary metastases-counting assay
Animals were sacrifised 2 weeks following intrave-
nous injection of 5´104 MC cells. The trachea was iso-
lated by midline chest incision and transected well above
carina.Two ml of Indian ink sulution (15% ink and 85%
distilled water, with two drops of ammonia water added)
were gently injected into the lung. The lungs were dis-
sected en block from thoracic cage and placed in petri
dish containing water for next 5 minutes. The pulmonal
lobi were separated and placed in Fekete’ solution (100
ml 70% ethanol, 10% formaldehyde and 5 mL of glacial
acetic acid). The lung metastases were counted under
lens control18.
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Statistical analysis
Distribution of data was tested with Kolmogorov-
-Smirnov test. Results were tested using analysis of vari-
ance.
Results
To evaluate the antimetastatic effect of spleen cells
from various periods of concomitant tumor immunity we
designed the experiments as follows. In first set of exper-
iment splenocytes from animals carrying tumor for 9, 16,
30 and 40 days were adoptively transferred intrave-
nously. A day after each animal was i.v. injected by the
suspension of tumor cells. The animals in control group
recived only tumor cells i.v. Two weeks later the number
of metastases was counted. The results in Figure 1 show
no diference between lung metastases number in ani-
mals that were adoptively transfered with normal sple-
nocytes and control. The best antimetastatic effect was
observed in animals adoptively transfered with spleno-
cytes from mice carrying s.c. MC for 9 days, while the
splenocytes from mice carrying s.c. MC for 16 days still
exibited antimetastatic effect, but weaker. The spleno-
cytes from mice carrying MC for 30 or 40 days did not
manifest antimetastatic effect as compared to groups
mentioned above (Figure 1).
To explain the cellular mechanism involved in the
weakening of antimetastatic effect of splenocytes from
donors carring tumors for 16, 30 and 40 days, we added
those cells to concomitant immune splenocytes (spleno-
cytes from mice carrying tumor for 9 days, spl9). That
suspension of cells was adoptively transfered to mice fol-
lowed by the i.v. injection of tumor cells. The results are
shown in Table 1. In agreement with previously shown
results, adoptively transfered concomitant immune sple-
nocytes (Group 3) reduced lung metastases number,
while adoptively transfered normal splenocytes (Group
2) showed no effect. Addition of splenocytes from mice
carrying subcutaneous tumor for 30 or 40 days abolished
antimetastatic effect of concomitant immune splenocy-
tes. Those results indicate that in spleen cell suspensions
from the period of CI weakening exists certain cells in-
volved in immunosupresion. Although the spleen cells
from mice carrying the tumor for 16 days lose their
antimetastatic effect, when added to spl9 did not sup-
press concomitant immune splenocytes. That phenome-
non could be explained by the dynamic of CI where the
16 day could be considered as transident period toward
CI weakening.
To evaluate the antimetastatic effect of macrophages
from various periods of concomitant tumor immunity, we
adoptively transferred i.v. macrophages from animals
carrying tumor for 9, 16, 30 and 40 days. A day after each
animal was i.v. injected by the suspension of tumor cells.
The mean number of lung metastases is shown in Figure
2. The strongest antimetastatic effect had macrophages
from mice carrying tumor for 16 days, while the macro-
phages from later CI periods became less effective. Ma-
crophages from the later CI period (mice carrying s.c. MC
for 40 days) not only lose their antimetastatic effect, but
also started to promote the tumor growth (Figure 2).
We presumed that in spleen cell suspensions from the
period of CI weakening (mice carrying s.c. MC for 30
and/or 40 days) exists certain cells involved in immuno-
supresion, we test if those cells could be macrophages.
For that purpose we added macrophages from the donors
carrying tumor for 9, 16, 30 and 40 days to concomitant
immune cells and that suspension was adoptively trans-
fferd a day before i.v. injection of tumor cells. The results
are shown in Table 2. The macrophages from mice carry-
ing MC s.c for 16 days increased the antimetastatic effect
of spl9. On the other hand, the macrophages from ani-
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Fig. 1. The antimetastatic effect of adoptively transferred spleen
cells from various periods of concomitant tumor immunity.
Animals in control group recived only 1´106 MC cells i.v. N re-
fers to splenocytes from non-tumor bearing mice. Adoptive trans-
fer was performed by i.v. injection 80´106 spleen cells following
by the i.v. injection of 1´106 MC cells.
*p0.05 versus control
TABLE 1
THE ANTIMETASTATIC EFFECT OF ADOPTIVELY TRANS-
FERRED SPLEEN CELLS (SPL) FROM VARIOUS PERIODS OF




The mean number of




4 spl9 + splN 7.7±2.7
5 spl9 + spl16 11.0±2.1
6 spl9 + spl30 36.4±1.7#
7 spl9 + spl40 31.8±4.9#
*Animals in group 1 recived only 1´106 MC cells i.v. Indices: 0, 9,
16, 30 and 40 refers to splenocytes from mice carrying MC sub-
cutaneously for 9, 16, 30 or 40 days. N refers to splenocytes from
non-tumor bearing mice. Adoptive transfer was performed by
i.v. injection 80´106 spleen cells following by the iv injection of
1´106 MC cells.
#p0.001 versus group 3
mals carrying MC for 30 or 40 days diminished anti-
metastatic effect of spl9 (Groups 5 and 6). Those results
indicate that macrophages are responsible for the late
period of CI weakening and suppresion.
To investigate weather prostaglandins can mediate
suppressive effect of macrophages from different periods
of CI weakening on concomitant immune splenocytes, we
used experiments with indomethacin. First we ruled out
the possible direct antimetastatic effect of indomethacin
(data not shown). Mice were adoptively transferred with
concomitant immune splenocytes and macrophages from
mice treated with indomethacin for 2 weeks before tu-
mor injection and carrying MC for 16, 30 and 40 days
(Table 3). Macrophages originating from the animals car-
rying MC for 30 or 40 days and treated with indo-
methacin lost their suppressive effect if being added to
concomitant immunogenic splenocytes. Furthermore,
antimetastatic effect of concomitant immunogenic sple-
nocytes became more pronounced (Table 3).
To clarify the mechanism of macrophage suppressive
effect; mice were adoptively transferred with 8´106 ma-
crophages from mice carrying subcutaneous MC for 9,
16, 30 and 40 days and treated with indomethacin for
two weeks a priori the experiment. One day after adop-
tive transfer, animals were intravenously injected with
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Fig. 2. The antimetastatic effect of adoptively transferred macro-
phages from various periods of concomitant tumor immunity.
Animals in control group recived only 1´106 MC cells i.v. Adop-
tive transfer was performed by i.v. injection of 8´106 macropha-
ges following by the i.v. injection of 1´106 MC cells. Indices: 9,
16, 30 and 40 refers to macrophages from mice carrying MC sub-
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Fig. 3. The antimetastatic effect of adoptively transferred macro-
phages from various periods of CI; the macrophage donors were
treated with indomethacin.
Animals in control group recived only 1´106 MC cells i.v. Adop-
tive transfer was performed by i.v. injection of 8´106 macropha-
ges from donors treated with indomethacin following by the i.v.
injection of 1´106 MC cells. Indices: 9, 16, 30 and 40 refers to
macrophages from mice carrying MC subcutaneously for 9, 16,
30 or 40 days.
*p0.001 versus control; ? p0.05 versus m9INDO
TABLE 2
THE ANTIMETASTATIC EFFECT OF ADOPTIVELY TRANS-
FERRED MACROPHAGES FROM VARIOUS PERIODS OF CI




The mean number of
lung metastases ± SE
1 — 42.2±1.8#
2 spl9 12.0±1.5
3 spl9 + m9 10.6±1.5
4 spl9 + m16 4.8±1.4#
5 spl9 + m30 30.0±1.8#
6 spl9 + m40 45.5±2.1#
* Animals in group 1 recived only 1´106 MC cells i.v.. Adoptive
transfer was performed by i.v. injection of 80´106 concomitant
immune splenocytes (spl9). Additionally to spl9 groups 3, 4, 5 and
6 recived 8´106 macrophages. Indices: 9, 16, 30 and 40 refers to
macrophages from mice carrying MC subcutaneously for 9, 16,
30 or 40 days. Adoptive transfer was followed up by the i.v. injec-
tion of 1´106 MC cells the day after.
#p0.01 versus group 2
TABLE 3
THE ANTIMETASTATIC EFFECT OF ADOPTIVELY TRANS-
FERRED MACROPHAGES FROM VARIOUS PERIODS OF
CI ADDED TO CONCOMITANT IMMUNE SPLENOCYTES (SPL9);





The mean number of
lung metastases ± SE
1 — 49.3±2.3#
2 spl9 11.8±1.4
3 spl9 + m16INDO 4.5±1.6#
4 spl9 + m30INDO 5.7±1.5#
5 spl9 + m40INDO 7.7±1.4
*Animals in group 1 recived only 1´106 MC cells i.v.. Adoptive
transfer was performed by i.v. injection of 80´106 concomitant
immune splenocytes (spl9). Additionally to spl9 groups 3, 4 and 5
recived 8´106 macrophages from donors treated with indome-
thacin. Indices: 16, 30 and 40 refers to macrophages from mice
carrying MC subcutaneously for 16, 30 or 40 days. Adoptive
transfer was followed up by the i.v. injection of 1´106 MC cells
the day after.
#p0.05 versus group 2
MC cells. Results are shown in Figure 3. The number of
lung metastases after adoptive transfer of macrophages
taken from the mice carrying subcutaneous MC for 30
and 40 days and treated with indomethacin decreased as
compared to the control (Figure 3). These macrophages
originating from the treated animals not only kept their
antimetastatic activity, but also that effect was more pro-
nounced as compared to the macrophages taken from the
animals carrying MC for 9 and 16 days. These results
suggest that inhibition of prostaglandine E2 synthesis by
indomethacin restored antimetastatic effect of concomi-
tant immune spleen cells.
Discussion
Concomitant immunity is a phenomenon recorded in
many tumor models, but its appearance time, develop-
ment and weakening depend on tumor type and experi-
mental model used19. Previously we analyzed the dy-
namic of CI in mammary carcinoma experimental model
(both primary and secondary tumors grow s.c.). In that
model CI attains maximal intensity about day 9 after in-
jection of primary tumor and becomes weaker after 16
day20. In here present study, splenocytes from mice carry-
ing MC for 30 or 40 days don’t have any antimetastatic
effect when being adoptively transferred (Figure 1). Fur-
thermore, splenocytes with the best antimetastatic effect
(spl9) lost their effect partially when being added to the
splenocytes from mice carrying MC for 16 days and com-
pletely when being added to the splenocytes from mice
carrying MC for 30 or 40 days (Table 1). That could be ex-
plained with the existence of immunosuppressive cells
that appear in that time in the spleen and that have been
previously shown to be macrophages15,21. To confirm
that, we adoptively transferred macrophages from differ-
ent period of CI. Since macrophages showed antimeta-
static effect on day 16, we assumed that antimetastatic
effect before that day was the act of lymphocytes as is in
concordance with literature15, while later on the role was
overtaken by macrophages (Figure 2). Moreover, the
adoptive transfer of macrophages from animal carrying
tumors for 30 and 40 days increased lung metastases
number and this confirmed the role of macrophages in
tumor progression22. We confirmed that splenocytes with
the best antimetastatic effect (spl9) lost their influence
when being added to the macrophages from mice carry-
ing MC for 30 or 40 days (Table 2).
Many authors have reported that macrophage acts via
secretion various cytokines such as prostaglandin E213,23.
Results from the experiment using adoptive transfer of
concomitant immunogenic splenocytes and macrophages
from different stages of CI showed that certain macro-
phages have lost their suppressive effect (Figure 3). That
includes macrophages that were taken 30 or 40 days fol-
lowing subcutaneous MC injection from the animals
treated with indomethacin for two weeks previously.
Moreover, these macrophages even increased antitumo-
ros effect of concomitant immunogenic splenocytes. Our
results indicated that prostaglandins are responsible for
suppressive macrophage effect in a period of CI weaken-
ing. However, beside PGE2 the role of other factors in
suppressive macrophage effect, such as nitric oxide, can’t
be excluded24,25.
The mechanism of macrophage suppressive effect in
period of CI weakening could be explained in two ways:
1) in that time there are citotoxic macrophages whose
citotoxicity is inhibited by suppressive macrophages,
suggesting the existence of two different populations of
macrophages; one that acts suppressive and the other
that is being suppressed; and 2) it is possible that cito-
toxic macrophages have lost their antitumor’s effect 30
days following MC injection and consequently became
suppressive cells, suggesting the existence of only one
suppressive population of macrophages. Results shown
in Table 3 indicate that there are two subpopulations of
macrophages. Namely, better antimetastatic effect of cell
suspension made of concomitant immunogenic spleno-
cytes and macrophages taken on the day 30 and 40 from
the animals treated with indomethacin could be explai-
ned by the inhibition of suppressive macrophages by
indomethacin. In that way, citotoxic macrophages that
were suppressed by that time, could became active and
intensify the effect of concomitant immunogenic sple-
nocytes. Results shown in Figure 3 are in consistence
with that explanation. If macrophages that were taken
from animals carrying MC for 30 or 40 days, and treated
with indomethacin, are being adoptively transferred they
have strong antitumoros effect, what differs from the
macrophages taken from untreated animals under same
other conditions (Figure 2). That phenomenon suggests
that citotoxic macrophages act freely without inhibition
of suppressive macrophages.
Important to mention is the fact that macrophages
whose antimetastic effect we studied, originated from
spleen, and we didn’t investigated the role of alveolar
macrophages in metastasing process. Also, it has to be
kept on mind that macrophages are not the only source
of prostaglandins in tumor host and that various tumor
types secrete great amounts of PGE226. Since, tumor cells
can be the source of prostaglandins (8), the indomethacin
effect on prostaglandins originating from tumor must be
also taken into consideration.
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DJELOVANJE INDOMETACINA NA ANTIMETASTASKI U^INAK MAKROFAGA:
MODEL POPRATNE IMUNOSTI
S A @ E T A K
Uloga makrofaga kao imunolo{kog antitumorskog ~imbenika ili poticatelja tumorskog rasta jo{ je uvijek puna nepo-
znanica. Istra`ili smo funkciju makrofaga u modelu pridru`ene imunosti koja se opisuje kao pojava odbacivanja sekun-
darnog tumora za vrijeme rasta primarnog tumora. Naime, pokazano je kako se za vrijeme slabljenja pridru`ene imu-
nosti mogu pojaviti tumorske metastaze. Upotrijebili smo arteficijalne plu}ne metastaze karcinoma dojke kako bismo
istra`ili utjecaj makrofaga iz razli~itih faza pridru`ene imunosti na razvoj mi{jih metastaza. Rezultati su pokazali kako
su makrofazi odgovorni za supresiju i kasnu fazu slabljenja pridru`ene imunosti. Kako bismo istra`ili jesu li prosta-
glandini odgovorni za supresivne u~inke makrofaga iskoristili smo pokuse s indometacinom. Dokazali smo kako inhi-
bicijom sinteze prostaglandina, indometacin oporavlja antimetastatski u~inak makrofaga pridru`ene imunosti.
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